402 related articles for article (PubMed ID: 25387507)
1. Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil.
Biot Sdel R; Franco JP; Lima RB; Pereira HN; Marques LP; Martins CJ
An Bras Dermatol; 2014; 89(6):980-4. PubMed ID: 25387507
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment with mycophenolate mofetil of four Japanese patients with pemphigus vulgaris.
Koga H; Ishii N; Hamada T; Karashima T; Nakama T; Yasumoto S; Hashimoto T
Eur J Dermatol; 2010; 20(4):472-5. PubMed ID: 20406724
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness and safety of rituximab in pemphigus vulgaris].
Alonso Sánchez A; García Rodríguez S; López Avila A; Rabell Iñigo S
Farm Hosp; 2010; 34(2):98-9. PubMed ID: 20304370
[No Abstract] [Full Text] [Related]
4. Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease?
Nigam R; Levitt J
J Drugs Dermatol; 2012 May; 11(5):622-5. PubMed ID: 22527431
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes in a cohort of patients with mucosal-predominant pemphigus vulgaris.
Ojaimi S; O'Connor K; Lin MW; Schifter M; Fulcher DA
Intern Med J; 2015 Mar; 45(3):284-92. PubMed ID: 25534017
[TBL] [Abstract][Full Text] [Related]
6. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
Kim MR; Kim HC; Kim SC
Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
[TBL] [Abstract][Full Text] [Related]
7. The actual management of pemphigus.
Daniel BS; Murrell DF
G Ital Dermatol Venereol; 2010 Oct; 145(5):689-702. PubMed ID: 20930702
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients.
Kasperkiewicz M; Shimanovich I; Meier M; Schumacher N; Westermann L; Kramer J; Zillikens D; Schmidt E
Br J Dermatol; 2012 Jan; 166(1):154-60. PubMed ID: 21910700
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus.
Doukaki S; Platamone A; Alaimo R; Bongiorno MR
J Dermatolog Treat; 2015 Feb; 26(1):67-72. PubMed ID: 24521072
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
Kong HH; Prose NS; Ware RE; Hall RP
Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
[TBL] [Abstract][Full Text] [Related]
11. Current and prospective pharmacotherapy for autoimmune hepatitis.
Czaja AJ
Expert Opin Pharmacother; 2014 Aug; 15(12):1715-36. PubMed ID: 24961409
[TBL] [Abstract][Full Text] [Related]
12. [Unexpected positive outcome following rituximab treatment in a patient with pemphigus vegetans resistant to conventional therapies: a case report].
Barbach Y; Baybay H; Mrabat S; Chaouche M; Elloudi S; Mernissi FZ
Pan Afr Med J; 2019; 32():101. PubMed ID: 31223391
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab.
Ahmed AR; Shetty S
Autoimmun Rev; 2015 Apr; 14(4):323-31. PubMed ID: 25499920
[TBL] [Abstract][Full Text] [Related]
14. Treatment of severe pemphigus vulgaris of the scalp with adjuvant rituximab and immunoadsorption.
Kamphausen I; Schulze F; Schmidt E; Zillikens D; Kunz M
Eur J Dermatol; 2012; 22(6):786-7. PubMed ID: 23114083
[No Abstract] [Full Text] [Related]
15. Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.
Werth VP; Joly P; Mimouni D; Maverakis E; Caux F; Lehane P; Gearhart L; Kapre A; Pordeli P; Chen DM;
N Engl J Med; 2021 Jun; 384(24):2295-2305. PubMed ID: 34097368
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy mechanisms in glomerulonephritis].
Polci R; Feriozzi S
G Ital Nefrol; 2011; 28(6):612-21. PubMed ID: 22167612
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of pemphigus].
van Beek N; Zillikens D; Schmidt E
Hautarzt; 2019 Apr; 70(4):243-253. PubMed ID: 30887081
[TBL] [Abstract][Full Text] [Related]
18. Superiority of Rituximab Over Mycophenolate Mofetil in the Treatment of Pemphigus Vulgaris: A Step Further in Its Approval as a First-Line Treatment?
Lemieux A; Saber M; Côté B
J Cutan Med Surg; 2022; 26(1):103-104. PubMed ID: 34320862
[No Abstract] [Full Text] [Related]
19. Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases.
Baum S; Gilboa S; Greenberger S; Pavlotsky F; Trau H; Barzilai A
J Dermatolog Treat; 2013 Dec; 24(6):427-30. PubMed ID: 23521340
[TBL] [Abstract][Full Text] [Related]
20. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent.
Esmaili N; Chams-Davatchi C; Valikhani M; Farshidfar F; Parvaneh N; Tamizifar B
Eur J Dermatol; 2008; 18(2):159-64. PubMed ID: 18424375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
